"Platform companies have the potential to compound revenues at over 25% in the long term. However, there is a misunderstanding about the profitability of these companies in the listed market space. Anand states that the current expenses are short-term and primarily linked to the current hyper growth phase. As these companies evolve and change consumer behavior, they can reduce costs and introduce monetization strategies."
The pharma and healthcare sector presents a study in contrasts in terms of performance, both financially and in the BT500 ranking - Issue Date: Dec 11, 2022
There is also muted demand for the much-hyped anti-viral drug Molnupiravir, which at least 13 firms are manufacturing including Sun Pharma, Cipla, Dr. Reddy’s, and Aurobindo Pharma, among others.